| Reshma Kewalramani |
CEO & President, Director |
$45.9M |
-$33.7M |
-42.3% |
Jul 30, 2024 |
| Bruce I. Sachs |
Director |
$27.6M |
-$10.2M |
-26.9% |
Aug 1, 2024 |
| Amit Sachdev |
EVP Chief Patient & Ext Af Off |
$26.8M |
-$5.8M |
-17.8% |
Jun 5, 2024 |
| Ourania Tatsis |
EVP, Chief Reg. & Quality Off. |
$22.6M |
-$3.67M |
-14% |
Jun 3, 2024 |
| Charles F. Wagner Jr |
EVP & Chief Financial Officer |
$21.7M |
-$5.24M |
-19.5% |
Jun 3, 2024 |
| Stuart A. Arbuckle |
Evp, Coo |
$21.5M |
-$11M |
-33.8% |
May 15, 2024 |
| Bastiano Sanna |
EVP, Cell & Genetic Therapies |
$13.4M |
|
|
May 5, 2023 |
| David Altshuler |
EVP, Chief Scientific Officer |
$11.1M |
-$6.11M |
-35.4% |
May 15, 2024 |
| Carmen Bozic |
EVP and CMO |
$11.1M |
-$16.7M |
-60.1% |
Aug 7, 2024 |
| Jonathan Biller |
EVP and Chief Legal Officer |
$7.66M |
-$939K |
-10.9% |
Feb 9, 2024 |
| Edward Morrow Atkinson III |
EVP, Chief Technical Ops. Off. |
$7.63M |
-$5.09M |
-40% |
Jun 11, 2024 |
| Jeffrey M. Leiden |
Executive Chairman, Director |
$5.21M |
-$20.1M |
-79.4% |
Aug 30, 2024 |
| Joy Liu |
SVP, General Counsel |
$4.03M |
|
|
Aug 15, 2022 |
| Diana Mckenzie |
Director |
$3.48M |
|
|
May 1, 2024 |
| Kristen Ambrose |
SVP & Chief Accounting Officer |
$3.14M |
-$1.05M |
-25.1% |
Apr 1, 2024 |
| Terrence C. Kearney |
Director |
$3M |
|
|
May 1, 2024 |
| Lloyd Carney |
Director |
$2.55M |
|
|
May 1, 2024 |
| Sangeeta N. Bhatia |
Director |
$2.22M |
-$1.29M |
-36.8% |
Aug 30, 2024 |
| Suketu Upadhyay |
Director |
$1.6M |
|
|
May 1, 2024 |
| Nancy Thornberry |
Director |
$788K |
|
|
May 1, 2024 |
| Michel Lagarde |
Director |
$731K |
|
|
May 1, 2024 |
| Jennifer Schneider |
Director |
$372K |
|
|
May 15, 2024 |
| Yuchun Lee |
Director |
$284K |
|
|
May 1, 2023 |
| Margaret G. Mcglynn |
Director |
$284K |
|
|
May 1, 2023 |
| Alan M. Garber |
Director |
$256K |
|
|
May 1, 2024 |